Sponsors (3)
The bill increases transparency and sponsor oversight of PBMs—helping beneficiaries, sponsors, and regulators understand true drug pricing—but does so at the cost of new compliance burdens, potential risks to proprietary data, and uneven impacts on smaller market participants.
Medicare beneficiaries, PDP sponsors, and taxpayers will receive standardized, machine‑readable PBM reports (including gross vs. net drug spending and amounts retained), improving drug‑pricing transparency, enabling cross‑plan comparisons, and supporting better oversight.
PDP sponsors and health systems can audit PBMs and obtain affiliate records and certifications to verify pricing guarantees and payments, strengthening sponsors' ability to detect and correct improper reimbursements or contract noncompliance.
Medicare beneficiaries and patients with chronic conditions will get disclosures about PBM affiliates, brokers, and incentive‑linked benefit designs, exposing conflicts of interest that can influence where enrollees fill prescriptions and enabling more informed choices.
PBMs, PDP sponsors, and ultimately taxpayers and enrollees will face increased administrative and compliance costs to collect, standardize, and submit detailed machine‑readable data; smaller PBMs and affiliated pharmacies may be disproportionately burdened, risking higher costs or reduced market competition.
Plans and PBMs will have to place proprietary or commercially sensitive information with HHS and auditors, raising the risk of leaks or misuse despite confidentiality limits and potentially harming competitive positions.
Requiring sponsors to rely on PBM‑provided data and certifications could shift liability and administrative burdens to PDP sponsors if PBMs fail to comply, exposing sponsors (and through them beneficiaries) to audit findings and enforcement actions.
Based on analysis of 2 sections of legislative text.
Requires PBMs serving Medicare drug plans to meet written transparency obligations and deliver annual machine-readable reports to plan sponsors (and HHS on request).
Official title: To amend title XVIII of the Social Security Act to establish pharmacy benefit manager reporting requirements with respect to prescription drug plans and MA-PD plans under Medicare part D.
Introduced February 4, 2025 by Greg Landsman · Last progress February 4, 2025
Requires pharmacy benefit managers (PBMs) that work for Medicare prescription drug plans (PDPs) and Medicare Advantage prescription drug plans (MA–PD) to meet new transparency and reporting requirements. For plan years beginning on or after January 1, 2028, PBMs must have written agreements imposing those obligations and must provide annual machine-readable reports to plan sponsors (and to HHS on request) containing detailed data on dispensed drugs, pricing concessions, and how pricing guarantees are calculated. The bill focuses on improving visibility into PBM practices by requiring clear definitions for pricing terms, identification of excluded drugs/claims/concessions, and WAC-based equivalents when other benchmarks are used. It creates recurring data delivery obligations (by July 1 annually) and expands sponsor and federal access to prior-plan-year PBM data to support oversight of drug pricing and guarantees.